Actavis Promethazine Codeine Cough Syrup

Actavis Promethazine Codeine Cough Syrup: Trusted Suppression for Unproductive Cough

When a persistent, dry, or otherwise unproductive cough disrupts daily life—stealing sleep and aggravating the respiratory tract—effective relief becomes a medical necessity. Actavis Promethazine Codeine Cough Syrup stands as a time‑honored solution within the antitussive category, formulated for cases where non‑prescription options fall short. This pharmaceutical preparation combines two complementary mechanisms: the central cough suppression of codeine phosphate and the antihistaminic, anti‑emetic properties of promethazine hydrochloride.

What It Is & How It Works

Actavis Promethazine Codeine is a prescription‑strength liquid indicated specifically for the temporary relief of coughs associated with upper respiratory tract infections or allergies. Codeine, an opioid antitussive, acts directly on the cough center in the medulla oblongata to raise the threshold for the cough reflex. Promethazine, a phenothiazine derivative, provides additional support by drying respiratory secretions and reducing the urge to cough through mild sedation and H1 receptor blockade. The synergy between these two active ingredients not only reduces cough frequency and intensity but also helps the patient rest—a critical component of recovery.

Benefits & Advantages

Unlike simple dextromethorphan syrups, this combination delivers dual‑action relief. Patients report faster reduction in night‑time coughing fits, improved sleep quality, and less throat irritation from repetitive coughing. The promethazine component also helps control nausea, a common side effect of many cough suppressants. For patients who have tried OTC options without success, Actavis Promethazine Codeine represents a reliable step‑up in therapeutic efficacy. Healthcare professionals value its predictable onset (30–45 minutes) and sustained duration of 4–6 hours, allowing for structured dosing schedules.

Safety & Responsible Usage Considerations

This product contains codeine, a controlled substance. It is intended strictly for patients over 12 years of age in non‑post‑operative settings. Codeine is metabolized by CYP2D6 into morphine; ultra‑rapid metabolizers may experience life‑threatening respiratory depression. Therefore, it is contraindicated in children undergoing tonsillectomy or adenoidectomy, and in any child under 12. Do not consume alcohol while using this syrup. Avoid driving or operating heavy machinery until you know how the medication affects you. Use only as directed—typically 5 mL every 4–6 hours as needed, not exceeding 4 doses per day. Tolerance, dependence, and withdrawal are possible with prolonged use beyond 7–14 days. Always obtain this medication through legitimate, licensed channels.

Longevity & Storage Life

When stored correctly, Actavis Promethazine Codeine Cough Syrup maintains full potency until the expiration date printed on the bottle—typically 24 months from manufacture. After opening, the syrup remains stable for 6 months provided it is not contaminated. Always use a clean, dry measuring device. Do not use the product if the liquid has changed color, become cloudy, or developed an unusual odor.

Ingredients / Composition

Each 5 mL dose contains: Codeine Phosphate 10 mg, Promethazine Hydrochloride 6.25 mg. Inactive ingredients: purified water, citric acid, sodium benzoate, propylene glycol, saccharin sodium, FD&C Red No. 40, and artificial grape flavor. The syrup is free from gluten and alcohol‑free in its standard formulation (verify batch labeling for alcohol‑free variants).

Build Trust & Customer Satisfaction

Thousands of returning patients and practitioners choose Actavis Promethazine Codeine because of its consistent quality, predictable pharmacokinetics, and palatable taste. For those with a valid medical need and a legitimate prescription, this product remains a gold standard. For more information on responsible sourcing and complete pharmaceutical guidelines, visit our homepage.

Learn more about responsible pharmaceutical access at Psychedelic Hive